Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval of agents to treat glioma, most notably Roche/Genentech/Chugai's Avastin, will drive market sales to more than double to more than $1.8 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Glioma finds that sales of Avastin, which is already used off-label to treat relapsed glioma and is in development for treating both relapsed and newly-diagnosed patients, will account for more than half of the total market in 2017. Sales of Schering-Plough's Temodar/Temodal, the current leading agent for glioma in both patient share and market share, will fall significantly from 2007 to 2017, owing to generic erosion.
According to the report, in addition to Avastin, the launches of Celldex Therapeutics/Pfizer's CDX-110 and Merck KGaA's cilengitide will also drive market growth. CDX-110 and cilengitide are being developed for use in newly diagnosed glioma patients and would each be used in combination with Temodar/Temodal. Additionally, overall sales for glioma therapies will be fueled by the launch of AstraZeneca's Recentin, which is in development for relapsed treatment.
"The treatment of glioma, especially the most malignant form--glioblastoma multiforme--is largely ineffective, and the prognosis for these patients is very poor," said Ramya Kollipara, Ph.D. analyst at Decision Resources. "Considerable opportunity remains in this market as currently-approved agents provide only modest improvements in patient outcomes, leaving a high level of unmet need."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Decision Resources Christopher Comfort 781-296-2597 firstname.lastname@example.org Decision Resources, Inc. Elizabeth Marshall 781-296-2563 email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
firstname.lastname@example.org, or Elizabeth Marshall of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/